喘息用スペーサーの世界市場：2023～2030年

吸入器スペーサー、ホールディングチャンバー、喘息用スペーサーはすべて、喘息のような呼吸器疾患の治療に使用される医療機器です。これらは、定量吸入器（MDI）を使用して薬剤を肺に吸入する方法を向上させるために作られます。喘息用スペーサーは、患者が処方された薬を完全に服用し、副作用のリスクを下げ、治療の全体的な効果を高めるために不可欠です。

喘息用スペーサー市場は、喘息、慢性閉塞性肺疾患（COPD）、気管支炎などの呼吸器疾患の有病率の上昇によって大きな影響を受けています。これらの病気が蔓延するにつれて、効率的な呼吸器治療薬の送達方法、特にスペーサーの必要性が高まっています。

喘息用スペーサーを使用する利点は、現在では患者や医療関係者によりよく理解されています。スペーサーは肺へのドラッグデリバリーの効果を高め、副作用の可能性を最小限に抑え、患者が処方薬を全量受け取ることを保証します。

市場力学：促進要因

喘息の有病率の増加

喘息と呼ばれる慢性呼吸器疾患は、肺の気道を拡大し炎症を起こします。Lancet誌によると、2020年の世界の喘息統計によると、喘息患者数は世界で合計3億3,900万人と増加しています。喘息は年齢に関係なく発症する可能性があるが、大人よりも子供の方が発症しやすいです。喘息の正確な原因は不明だが、遺伝的要因と環境的要因の両方が関係していると考えられています。喘鳴、咳、胸部圧迫感、息切れはすべて喘息の典型的な徴候です。

Global Asthma Networkが作成したGlobal Asthma Report 2022によると、喘息はインドでおよそ3500万人に影響を及ぼしています。同レポートによると、過小診断と不十分な治療が、インドにおける喘息との闘いの大きな障害となっています。喘息はまた、インドの小児の大部分にも影響を及ぼしています。喘息をコントロールするための介入は、地域社会の教育と、プライマリーヘルスケアレベルで必要な医薬品や備品を優先的に提供することから始めなければならないです。

喘息の治療のために、ゼロスタットVTスペーサー透明吸入スペースが意図されています。この製品は高品質の材料で作られており、非常に長い間使用することができます。ゼロスタットVTスペーサー透明吸入スペースと呼ばれるドラッグデリバリーシステムは、喘息患者の治療に使用されます。これは、エアロゾル化操作法を採用した吸入器です。

認識と教育の欠如

喘息用スペーサーを使用する利点に関する知識の欠如や、適切な使用方法に関する患者教育が不十分であることが、市場拡大の妨げとなる可能性があります。吸入器でスペーサーを使用する利点は、多くの患者やヘルスケア専門家によって十分に理解されていない可能性があります。コストは喘息用スペーサーの使用にとって大きな障害となりえます。特に保険に加入していない患者や定期的に交換しなければならない患者にとっては、これらの器具は高額になる可能性があります。ネブライザーやドライパウダー吸入器（DPI）は、患者によってはスペーサー付きMDIよりも好まれる場合があります。喘息用スペーサーの需要は、個人の嗜好や特定の器具を使用する快適さのレベルによって異なる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 喘息の有病率の増加
  • 抑制要因
    • 認識と教育の欠如
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• SWOT分析
• 特許分析
• DMIオピニオン

第6章 COVID-19分析

第7章 タイプ別

• エアロチャンバー
• オプティチャンバー
• ボリューマチック
• インスピレーズ

第8章 流通チャネル別

• 小売薬局
• 病院薬局
• eコマース

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他のアジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Cipla Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Koninklijke Philips N.V.
• Deposition Pulmonaire des Medicaments SAS
• Monaghan Medical Corporation
• Duomed
• Others

第12章 付録

Overview

Inhaler spacers, holding chambers, and asthma spacers are all medical devices used to treat respiratory disorders like asthma. They are made to enhance the way medication is inhaled into the lungs using metered-dose inhalers (MDIs). Asthma spacers are essential in ensuring that patients take their prescription medication in its entirety, lowering the risk of side effects, and enhancing the overall efficacy of treatment.

The market for asthma spacers has been significantly impacted by the rising prevalence of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The need for efficient respiratory medicine delivery methods, particularly spacers, has increased as these illnesses become more widespread.

The advantages of employing asthma spacers are now better understood by patients and healthcare practitioners. Spacers increase the effectiveness of drug delivery to the lungs, minimizing the chance of adverse effects and guaranteeing that patients receive the entire quantity of their prescription medications.

Market Dynamics: Drivers

The Increasing Prevalence of Asthma

A chronic respiratory condition called asthma enlarges and inflames the lungs' airways. As per the Lancet, the asthma statistics worldwide for 2020 reported that the number of persons with asthma, a total of 339 million worldwide, is rising. Although asthma can afflict people of any age, children are more likely than adults to get the condition. Although the exact cause of asthma is unknown, it is thought to be a result of both hereditary and environmental factors. Wheezing, coughing, chest tightness, and shortness of breath are all typical signs of asthma.

The Global Asthma Report 2022, prepared by Global Asthma Network, shows that Asthma affects roughly 35 million people in India. According to the report, underdiagnosis and insufficient treatment are significant obstacles to the fight against asthma in India. Asthma also affects a significant portion of children in India. Interventions for controlling asthma must start with community education and the prioritization of required drugs and supplies at the primary healthcare level.

For the treatment of asthma, the Zerostat VT Spacer Transparent inhaler space is intended. This item is made of high-quality materials and will last you for a very long time. A drug delivery system called a Zerostat VT Spacer Transparent Inhaler Space is used to treat asthma patients. It is an inhaler that employs the aerosolization method of operation.

Lack of Awareness and Education

Lack of knowledge regarding the advantages of employing asthma spacers and insufficient patient education on their proper use can impede market expansion. The benefits of utilizing spacers with inhalers may not be fully understood by many patients and healthcare professionals. Cost can be a major obstacle to the use of asthma spacers. These devices might be costly for some patients, especially if they do not have insurance or if they have to replace them regularly. Nebulizers and dry powder inhalers (DPIs) may be preferred by some patients over MDIs with spacers. Demand for asthma spacers may vary depending on individual preferences and level of comfort using particular devices.

Segment Analysis

The global asthma spacers market is segmented based on type, distribution channel and region.

The aerochambers segment accounted for approximately 45.6% of the market share

Aerochambers are cutting-edge medical tools made to make it easier for people with asthma, COPD, or other respiratory disorders to breathe. Aerochambers are made up of a plastic tube that allows the drug spray to reach the patient, a mask that goes over the face or a mouthpiece on the front, and sometimes a plastic cover for the medication that is being administered that is attached to the back.

Depending on the age range, different models of aerochambers are available. Some manufacturers opt for a distinct model for each age range, such as one for children aged 1-6 and another for those above the age of 6, while others use a single aerochamber with a detachable aerochamber mask.

Biosynex Aerochambers come in infant, child, and adult sizes and are assured to be latex and bisphenol A-free. They are a crucial component of effective respiratory disease treatment. Biosynex aerochambers are designed for people of all ages who still find it difficult to take the medication with a metered dose inhaler.

Geographical Penetration

The Increasing Prevalence of Ashma and Advanced Healthcare Infrastructure

North America has been a dominant force in the global asthma spacers market. Where a person lives has a big impact on their asthma. People with asthma have a better chance of managing and treating their condition if they have access to inexpensive, quality healthcare, clean air, and stable economic conditions.

In April 2023, the American Lung Association estimates that 41.9 million Americans have ever had an asthma diagnosis. A persistent illness that affects the airways is asthma. Chest pain, coughing, and wheezing are some symptoms that can come and go. All ages are affected by asthma; however, it most often develops in children.

One sort of spacer that has a one-way valve at the mouthpiece is a valved holding chamber. More than just "space" between the mouth and the medication is provided by these devices. Additionally, it holds and traps medication, allowing patients to take a moment to exhale deeply. This makes it possible to inhale the complete pharmaceutical dose.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide. People with pre-existing respiratory illnesses, such as asthma, became more aware of their health as a result of the pandemic, which brought to light the significance of respiratory health. The demand for asthma spacers and other breathing devices may have increased as a result of the greater awareness.

Telemedicine and remote monitoring are two strategies that many healthcare providers have used to lower the danger of exposure to COVID-19. Through virtual consultations, patients with asthma and other respiratory disorders may have received advice on how to use and manage devices, thereby increasing the adoption of spacers.

By Product Type

• Aerochamber
• Optichamber
• Volumatic
• Inspirease

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include: Cipla Inc, Koninklijke Philips N.V., Deposition Pulmonaire des Medicaments SAS, Monaghan Medical Corporation, Truedell Medical International, Duomed, PARI GmbH, Laboratoire ProtecSom and Haag-streit group among others.

Why Purchase the Report

• To visualize the global asthma spacers market segmentation based on type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of asthma spacers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global asthma spacers market report would provide approximately 46 tables, 53 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Prevalence of Asthma
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness and Education
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. SWOT Analysis
• 5.7. Patent Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Aerochamber*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Optichamber
• 7.4. Volumatic
• 7.5. Inspirease

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Retail Pharmacy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Hospital Pharmacy
• 8.4. E-Commerce

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. UK
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Cipla Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Koninklijke Philips N.V.
• 11.3. Deposition Pulmonaire des Medicaments SAS
• 11.4. Monaghan Medical Corporation
• 11.5. Duomed
• 11.6. Others

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us